Superficial Serratus Plane Block for Modified Radical Mastectomy and Axillary Lymph Node Disection

Analgesic Efficiency of Superficial Serratus Plane Block for Modified Radical Mastectomy and Axillary Lymph Node Disection: Randomized Controlled Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03341234

Enrollment

Registered

2017-11-14

Start date

2016-11-01

Completion date

2017-08-01

Last updated

2017-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Consumption, Pain, Postoperative, Postoperative Analgesia

Keywords

Superficial Serratus Plane Block, Modified Radical Mastectomy, Axillary Lymph Node Disection, bupivacaine

Brief summary

Breast cancer is the most common type of cancer in women. Mastectomy and axillary lymph node disection are commonly performed as part of the cancer management. This surgery can cause significant postoperative pain. The serratus plane block (SPB) has been described for analgesia of the hemithorax and reported for many cases such as thoracoscopy, shoulder arthroscopy, breast surgery and axillary lymph node dissections. Serratus plane block may be a viable alternative to current regional anaesthetic techniques such as thoracic paravertebral and central neuraxial blockade. The aim of this study is to determine effectiveness of ultrasound guided superficial serratus plane block in patients undergoing modified radical mastectomy and axillary lymph node dissection surgery.

Interventions

DRUGBupivacaine

30 ml %0,25 bupivacaine

DRUGSaline

2 ml saline subcutaneously

DEVICEUltrasound

Ultrasound guided block

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologist's physiologic state I-III patients undergoing Modified Radical Mastectomy and Axillary Lymph Node Disection

Exclusion criteria

* chronic pain, bleeding disorders, renal or hepatic insufficiency,patients on chronic non-steroidal anti-inflammatory medications

Design outcomes

Primary

Measure	Time frame	Description
Opioid Consumption	First 24 hours total opioid consumption	First 24 hours total fentanyl consumption with patient controlled analgesia

Secondary

Measure	Time frame	Description
Visual analog pain score	postoperative first hour	Post operative pain will be evaluated with a Visual Analogue Scale (VAS) score of 0-10 (0= no pain and 10= worst imaginable pain) at first hour postoperatively.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026